
Amer Beitinjaneh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3190812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
2	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology, 2023, 41, 555-567.	1.6	82
3	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood, 2022, 139, 1330-1339.	1.4	52
4	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	7.2	45
5	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
6	Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899.	2.0	34
7	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
8	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	2.2	31
9	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
10	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	1.2	18
11	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 177.e1-177.e8.	1.2	16
12	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
13	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> â^' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
14	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
15	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. Critical Care Medicine, 2022, 50, 81-92.	0.9	13
16	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplantation and Cellular Therapy, 2022, 28, 34-42.	1.2	13
17	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
18	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11

Amer Beitinjaneh

#	Article	IF	CITATIONS
19	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	1.2	10
20	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	3.5	10
21	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
22	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
23	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplantation and Cellular Therapy, 2022, 28, 603.e1-603.e7.	1.2	4
24	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 483.e1-483.e7.	1.2	2